The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Midatech Pharma plc

10 Jun 2020 12:57

RNS Number : 5618P
Berenberg
10 June 2020
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Joh. Berenberg, Gossler & Co. KG

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Midatech Pharma PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

9th June 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

0.1 pence ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

47,125

0.12%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

47,125

0.12%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit- GBP

0.1 pence ordinary shares

Purchase

10000

24

0.1 pence ordinary shares

Purchase

5000

23.4

0.1 pence ordinary shares

Purchase

10000

22.4

0.1 pence ordinary shares

Purchase

2012

22.45

0.1 pence ordinary shares

Purchase

10514

22.65

0.1 pence ordinary shares

Purchase

6000

22.7

0.1 pence ordinary shares

Purchase

8308

22.8

0.1 pence ordinary shares

Purchase

1733

22.82

0.1 pence ordinary shares

Purchase

2209

22.65

0.1 pence ordinary shares

Purchase

24000

22.25

0.1 pence ordinary shares

Purchase

8996

22.3

0.1 pence ordinary shares

Purchase

8996

22.3

0.1 pence ordinary shares

Purchase

53571

22.41

0.1 pence ordinary shares

Purchase

10508

23.85

0.1 pence ordinary shares

Purchase

2500

24

0.1 pence ordinary shares

Purchase

4081

15.25

0.1 pence ordinary shares

Purchase

1765

15.25

0.1 pence ordinary shares

Purchase

5677

15.25

0.1 pence ordinary shares

Purchase

8888

15.25

0.1 pence ordinary shares

Purchase

2720

15.25

0.1 pence ordinary shares

Purchase

10122

15.25

0.1 pence ordinary shares

Purchase

10793

15.25

0.1 pence ordinary shares

Purchase

8526

15.5

0.1 pence ordinary shares

Purchase

1714

18.5

0.1 pence ordinary shares

Purchase

20000

18.5

0.1 pence ordinary shares

Purchase

4080

18.5

0.1 pence ordinary shares

Purchase

10000

18.5

0.1 pence ordinary shares

Purchase

55000

18.5

0.1 pence ordinary shares

Purchase

3743

18.5

0.1 pence ordinary shares

Purchase

19803

16.5

0.1 pence ordinary shares

Sale

6016

24.8

0.1 pence ordinary shares

Sale

8040

24.8

0.1 pence ordinary shares

Sale

3984

24.8

0.1 pence ordinary shares

Sale

15969

24.8

0.1 pence ordinary shares

Sale

20000

25

0.1 pence ordinary shares

Sale

1007

25

0.1 pence ordinary shares

Sale

1000

24.99999

0.1 pence ordinary shares

Sale

2756

24.96

0.1 pence ordinary shares

Sale

17338

24.8

0.1 pence ordinary shares

Sale

10080

24.8

0.1 pence ordinary shares

Sale

1209

24.8

0.1 pence ordinary shares

Sale

3989

24.75

0.1 pence ordinary shares

Sale

2044

24.45

0.1 pence ordinary shares

Sale

2027

24.37

0.1 pence ordinary shares

Sale

4123

24.25

0.1 pence ordinary shares

Sale

2037

24.25

0.1 pence ordinary shares

Sale

15031

24.25

0.1 pence ordinary shares

Sale

41650

24

0.1 pence ordinary shares

Sale

5000

23

0.1 pence ordinary shares

Sale

10000

22.4

0.1 pence ordinary shares

Sale

28470

22.98

0.1 pence ordinary shares

Sale

5000

22.6

0.1 pence ordinary shares

Sale

7365

23

0.1 pence ordinary shares

Sale

21726

23.2

0.1 pence ordinary shares

Sale

25000

23.4

0.1 pence ordinary shares

Sale

25000

23.6

0.1 pence ordinary shares

Sale

20000

23.8

0.1 pence ordinary shares

Sale

20000

24.2

0.1 pence ordinary shares

Sale

14558

24.2

0.1 pence ordinary shares

Sale

5000

24.4

0.1 pence ordinary shares

Sale

12873

24.4

0.1 pence ordinary shares

Sale

10450

24.4

0.1 pence ordinary shares

Sale

5000

24.4

0.1 pence ordinary shares

Sale

25000

24.4

0.1 pence ordinary shares

Sale

2500

24.25

0.1 pence ordinary shares

Sale

4000

24.25

0.1 pence ordinary shares

Sale

10217

24.35

0.1 pence ordinary shares

Sale

1500

23.8

0.1 pence ordinary shares

Sale

26824

24.4

0.1 pence ordinary shares

Sale

5670

24.6

0.1 pence ordinary shares

Sale

5369

24.6

0.1 pence ordinary shares

Sale

3024

24.6

0.1 pence ordinary shares

Sale

10000

24.4

0.1 pence ordinary shares

Sale

5000

24.4

0.1 pence ordinary shares

Sale

39231

24.2

0.1 pence ordinary shares

Sale

30385

24.4

0.1 pence ordinary shares

Sale

8078

24.6

0.1 pence ordinary shares

Sale

4255

22

0.1 pence ordinary shares

Sale

11061

18

0.1 pence ordinary shares

Sale

1111

18

0.1 pence ordinary shares

Sale

10000

18

0.1 pence ordinary shares

Sale

100000

18

0.1 pence ordinary shares

Sale

10000

19

0.1 pence ordinary shares

Sale

500

15.5

0.1 pence ordinary shares

Sale

10000

16

0.1 pence ordinary shares

Sale

25000

20

0.1 pence ordinary shares

Sale

25000

20

0.1 pence ordinary shares

Sale

1984

19.8999

0.1 pence ordinary shares

Sale

10020

19.89999

0.1 pence ordinary shares

Sale

5025

19.89999

0.1 pence ordinary shares

Sale

14903

19.8999

0.1 pence ordinary shares

Sale

50211

19.89999

0.1 pence ordinary shares

Sale

3818

19.89999

0.1 pence ordinary shares

Sale

100000

19.89999

0.1 pence ordinary shares

Sale

5000

20

0.1 pence ordinary shares

Sale

800000

20.03125

0.1 pence ordinary shares

Sale

38000

17.5

0.1 pence ordinary shares

Sale

200000

18.5

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

10th June 2020

Contact name:

Daniel Stephens

Telephone number*:

020 3207 7881

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETEAFKEFSLEEFA
Date   Source Headline
10th Mar 20169:00 amRNSNotice of Audited Full Year Results
29th Feb 20167:00 amRNSMidatech Celebrates Rare Disease Day
23rd Feb 20168:59 amRNSHolding(s) in Company
6th Jan 20167:00 amRNSPre-close Trading Update
4th Jan 20167:00 amRNSLicencing agreement signed with Emergex Vaccines
30th Dec 20157:00 amRNSClosing of product acquisition
23rd Dec 20157:00 amRNSIssue of Equity
18th Dec 20151:09 pmRNSDirector/PDMR Shareholding
18th Dec 20157:00 amRNSMidatech agrees to acquire Zuplenz®,
14th Dec 20157:00 amRNSAgreement with Centurion Pharma
9th Dec 20157:10 amRNSMidatech Appoints RBC as Joint Broker
7th Dec 20157:00 amRNSClosing of acquisition
3rd Dec 20152:34 pmRNSMerger Update: Amount of New Shares to be Issued
3rd Dec 20157:00 amRNSMerger Update: Acquisition of DARA BioSciences
19th Nov 20159:30 amRNSSupplemental Disclosure
25th Sep 20157:00 amRNSIssue of equity from exercise of share options
14th Sep 20157:00 amRNSHalf Yearly Report
2nd Sep 20159:10 amRNSMidatech to Present at Rodman & Renshaw Conference
2nd Sep 20157:00 amRNSNotice of Interim Results
13th Aug 20157:00 amRNSOcular Agreement with Ophthotech
12th Aug 20157:00 amRNSFiling of Form F-4 Registration Statement with SEC
23rd Jul 20157:00 amRNSInitiation of Phase IIa study of insulin delivery
26th Jun 201512:38 pmRNSDirector's Share Purchase
25th Jun 20153:03 pmRNSMidatech Pharma-Posting of Annual Financial Report
24th Jun 20157:00 amRNSDirector/PDMR Shareholding
23rd Jun 20153:43 pmRNSDirector/PDMR Shareholding
4th Jun 20157:00 amRNSProposed Acquisition of DARA BioSciences, Inc.
26th May 20152:05 pmRNSResult of AGM
26th May 20157:01 amRNSAnnual General Meeting
24th Apr 20154:12 pmRNSIssue of equity from exercise of share options
22nd Apr 20159:41 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th Apr 20157:04 amRNSPreliminary Results
14th Apr 20157:00 amRNSResearch Collaboration Signed
1st Apr 20157:00 amRNSMidatech Pharma - Board Change
31st Mar 20151:42 pmRNSChange of Registered Office Address
26th Mar 20157:00 amRNSNotice of Maiden Preliminary Results
23rd Mar 201510:43 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Mar 20157:00 amRNSResearch Collaboration Signed with Global Pharma
24th Feb 20157:00 amRNSTrading Update
19th Feb 20157:00 amRNSPositive Results in Proof-of-Concept Study
2nd Jan 20158:30 amRNSHolding(s) in Company
17th Dec 20147:00 amRNSAward of EU grant funding
9th Dec 20143:37 pmRNSHolding(s) in Company
8th Dec 201412:00 pmRNSMidatech Pharma acquires Q Chip

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.